Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

Lee, Kyu-Sun; Noh, Junghyun; Park, Seong‐Mi; Choi, Kyung Mook; Kang, Seok‐Min; Won, Kyu-Chang; Cho, Hyun‐Jai; Moon, Min Kyong

doi:10.4093/dmj.2022.0420

Cited by 7 publications

(8 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall prevalence of HF in South Korea is increasing, and reached 2.2% in 2018, 26 which was similar to that reported globally 27,28 . Approximately 30%‐40% of patients with diabetes have HF, 26 that is, people with diabetes are at a high risk of developing HF and, in most cases, exhibit no typical symptoms or signs 29,30 . Most cardiovascular outcome trials (CVOTs) have confirmed that DPP‐4 inhibitors are safe in terms of the risk of cardiovascular events, but a concern about the risk of HF was raised by the SAVOUR‐TIMI53 study (saxagliptin) and the EXAMINE study (alogliptin) 7,8 .…”

Section: Discussionmentioning

confidence: 60%

“…27,28 Approximately 30%-40% of patients with diabetes have HF, 26 that is, people with diabetes are at a high risk of developing HF and, in most cases, exhibit no typical symptoms or signs. 29,30 by the SAVOUR-TIMI53 study (saxagliptin) and the EXAMINE study (alogliptin). 7,8 Although a causal relationship is unclear and has not been observed in other CVOTs of DPP-4 inhibitors, the use of DPP-4 inhibitors requires caution for patients who have, or are suspected of having, impaired cardiac function.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study

Chung

Moon

Hong

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim: To investigate the effects of gemigliptin on cardiac function and compare the effects of gemigliptin and glimepiride in patients with type 2 diabetes (T2D).Materials and Methods: Sixty T2D patients being treated with metformin were assigned to a gemigliptin group (50 mg daily) or a glimepiride group (2 mg daily) for 24 weeks. The preadjudicated extension period was up to 52 weeks. Glucose metabolism variables and cardiac biomarkers were measured. Echocardiography was used to evaluate cardiac functions.Results: The HbA1c levels decreased significantly from 8.1% ± 0.6% to 6.8% ± 0.6% in the gemigliptin group and from 8.1% ± 0.6% to 7.0% ± 0.7% in the glimepiride group, without a between-group difference. Gemigliptin reduced insulin resistance, high sensitivity C-reactive protein and low-density lipoprotein cholesterol levels, and blood pressure, and increased adiponectin level compared with glimepiride therapy.Gemigliptin induced favourable changes in body composition. Left ventricular enddiastolic volume decreased in the gemigliptin group but increased in the glimepiride group, with a borderline between-group difference. Cardiac biomarkers did not change significantly in either group. At 52 weeks, the HbA1c levels in both groups increased slightly; 7.3% ± 0.8% in the gemigliptin group versus 7.7% ± 1.3% in the glimepiride group, without a between-group difference.Conclusions: Gemigliptin had a comparable glucose-lowering efficacy without deleterious effects on cardiac functions or on biomarkers reflective of myocardial injury or heart failure during the 24-week observation period. However, larger, longer-term studies are needed to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study

Chung

Moon

Hong

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…The prevalence of comorbid diabetes mellitus (DM) in HF patients is 20–36% in Korea and 25–45% in Western countries [ 3 , 67 ]. Managing DM is crucial in HF patients [ 68 ].…”

Section: Special Consideration For Specific Comorbiditiesmentioning

confidence: 99%

Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction

Bak,

Choi

2023

Korean J Intern Med

View full text Add to dashboard Cite

With the increasing number of medications demonstrating mortality benefits in heart failure with reduced ejection fraction (HFrEF), the pharmacological treatment of HFrEF is entering a new phase. To enhance outcomes in heart failure patients through medical treatment, the choice of appropriate medications and simultaneous and rapid uptitration are critical. However, there are several challenges encountered during this medication uptitration, including issues like hypotension, fatigue, worsening renal function, and hyperkalemia. This paper addresses strategies for effectively managing these challenges to successfully reach the maximum tolerated dose in patients. Additionally, it will discuss the management of comorbidities often associated with heart failure, the importance of exercise and rehabilitation, and the significance of proper nutrition intake, in addition to guideline-directed medical therapy.

show abstract

“…Despite the dramatic improvement in short-and long-term outcomes of HF with established guideline-directed medical therapy, HF remains a significant health burden worldwide with increasing prevalence [9][10][11][12][13]. Current HF guidelines emphasize the importance of individualized assessment and management according to HF phenotypes [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Epicardial Adipose Tissue and Heart Failure, Friend or Foe?

Cho,

Park

2024

Diabetes Metab J

Self Cite

View full text Add to dashboard Cite

Heart failure (HF) management guidelines recommend individualized assessments based on HF phenotypes. Adiposity is a known risk factor for HF. Recently, there has been an increased interest in organ-specific adiposity, specifically the role of the epicardial adipose tissue (EAT), in HF risk. EAT is easily assessable through various imaging modalities and is anatomically and functionally connected to the myocardium. In pathological conditions, EAT secretes inflammatory cytokines, releases excessive fatty acids, and increases mechanical load on the myocardium, resulting in myocardial remodeling. EAT plays a pathophysiological role in characterizing both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). In HFrEF, EAT volume is reduced, reflecting an impaired metabolic reservoir, whereas in HFpEF, the amount of EAT is associated with worse biomarker and hemodynamic profiles, indicating increased EAT activity. Studies have examined the possibility of therapeutically targeting EAT, and recent studies using sodium glucose cotransporter 2 inhibitors have shown potential in reducing EAT volume. However, further research is required to determine the clinical implications of reducing EAT activity in patients with HF.

show abstract

Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement

Cited by 7 publications

References 108 publications

Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study

Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study

Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction

Epicardial Adipose Tissue and Heart Failure, Friend or Foe?

Contact Info

Product

Resources

About